Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL3818 Monotherapy or Combination Therapy in Advanced Solid Tumors
NCT07811297Phase 2Not yet recruiting
- Sponsor
- Advenchen Laboratories
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 2 trial of catequentinib in endometrial cancer (EC), ovarian cancer, soft tissue sarcoma (STS), glioblastoma (GBM), non-small cell lung cancer (NSCLC), sponsored by Advenchen Laboratories. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
catequentinib
03
Conditions
endometrial cancer (EC)ovarian cancersoft tissue sarcoma (STS)glioblastoma (GBM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07811297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811297.